Losartan Potassium
NDC Package 16590-952-60

11-digit billing NDC: 16590095260

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Losartan Potassium is hypertension    Losartan potassium tablets are indicated for the treatment of hypertension. Marketed by Stat Rx Usa Llc, this product is identified by NDC 16590-952 and is authorized under FDA application ANDA090467.

Identification & Billing

NDC Package Code
16590-952-60
Package Description
60 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
16590095260
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Losartan Potassium
Dosage Form
-
Usage Information
Hypertension    Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics.Hypertensive Patients with Left Ventricular Hypertrophy     Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS  Race, CLINICAL PHARMACOLOGY, , .) Pharmacodynamics and Clinical EffectsReduction in the Risk of StrokeRacein 2 Patients NephropathyTypeDiabeticLosartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY). Pharmacodynamics and Clinical Effects

Regulatory & Marketing

Labeler Name
Stat Rx Usa Llc
FDA Application #
ANDA090467
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-06-2010
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (16590-952). Click a package code to view its specific billing and regulatory data.

30 TABLET in 1 BOTTLE
90 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-952-60 identifies a specific commercial package of 60 tablet in 1 bottle of Losartan Potassium, labeled by Stat Rx Usa Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa Llc on October 06, 2010. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590095260. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-952-60
11-Digit CMS (5-4-2)
16590-0952-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.